West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$299.81 USD
+0.01 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $299.98 +0.17 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$299.81 USD
+0.01 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $299.98 +0.17 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Has West Pharmaceutical Services (WST) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
Is West Pharmaceutical Services (WST) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
COVID-19 Vaccine Rollout Challenges Put These Stocks in Focus
by Rimmi Singhi
With COVID-19 vaccine on the horizon, cold-chain storage stocks including TT, CARR and TMO; vial makers like GLW and WST; and logistic operators including UPS and FDX are set to hog the limelight.
Tivity Health's (TVTY) Shares Fall Despite Q3 Earnings Beat
by Zacks Equity Research
Tivity Health (TVTY) reports solid revenue growth in its Nutrition arm in the third quarter due to strength in Nutrisystem brand DTC.
Has West Pharmaceutical Services (WST) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
Owens & Minor's (OMI) Shares Fall Despite Q3 Earnings Beat
by Zacks Equity Research
Owens & Minor (OMI) reports solid revenue growth in its Global Products arm in the third quarter due to strength in PPE sales.
Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y
by Zacks Equity Research
In Q3, Hill-Rom's (HRC) bed orders and backlog in the United States accelerates with sequential recovery in Patient Support Systems arm.
Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.
Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
CVS Health (CVS) Q3 Earnings Top Estimates, 2020 View Up
by Zacks Equity Research
CVS Health's (CVS) Q3 pharmacy claims processed rise attributable to strong net new business, partially offset by reduced new therapy prescriptions.
Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.
Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.
Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.
Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.
Novo Nordisk (NVO) Catches Eye: Stock Jumps 7.2%
by Zacks Equity Research
Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Hologic (HOLX) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in fourth-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.
Bruker's (BRKR) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Bruker's (BRKR) third-quarter 2020 results reflect dismal performances by two of the reporting segments and geographies due to coronavirus-led business disruptions.
Chemed's (CHE) Shares Up on Q3 Earnings and Revenue Beat
by Zacks Equity Research
Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.
Teleflex (TFX) Q3 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
Teleflex (TFX) witnesses significant sequential improvement in segmental performance on gradual recovery of the economy.
Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal segmental performance in the third quarter of 2020 due to pandemic-led business disruptions.
NuVasive (NUVA) Q3 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
NuVasive (NUVA) registers strong international performance in Q3 along with several spinal hardware product lines growing at high single digits or more.